Lajos Pusztai MD

Breast Cancer, Hematologic Oncology

Professor of Medicine

300 George St, New HavenSuite 120New Haven, CT 06520
Fax+1 203-785-5792

Dr. Pusztai is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pusztai's full profile Already have an account?

Education & Training

University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1996 - 1999
Rochester Regional Health/Unity Internal MedicineResidency, Internal Medicine, 1992 - 1996
Semmelweis UniversityClass of 1986

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

TX State Medical License 1997 - 2027
CT State Medical License 2012 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014, 2016-2017

Clinical Trials

Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients
COMPLETED
PHASE1, PHASE2
Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast Cancer
COMPLETED
PHASE3
Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer
COMPLETED
PHASE3

Publications & Presentations

PubMed

Inhibition of Acetyl-CoA-carboxylase induces endoplasmic reticulum stress and augments the efficacy of anti-cancer therapies.
Naing Lin Shan, Henriette Balinda, Jiawei Dai, Yueyue Wang, Hao-Kuen Lin
Clinical Cancer Research. 2026-08-03
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.
Claudine Isaacs, Rita Nanda, Christina Yau, A Jo Chien, Dawn L Hershman
JAMA Oncology. 2026-07-30
Distillation enables scalable high-fidelity virtual screening across ultra-large chemical libraries.
Jiawei Dai, Yueyue Wang, Naing Lin Shan, Marco Mariani, Zimeng Yu
Biorxiv. 2026-07-03

Journal Articles

Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women with ERBB2 (HER2)–Positive Breast Cancer
Lajos Pusztai, MD, JAMA Network Open
Association of T-cell Receptor Repertoire Use with Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast CancerSecondary Analysis of the NeoALTT...
Lajos Pusztai, Jose Baselga, JAMA

Lectures

Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Why Do We Care About Molecular Evolution in Breast Cancer?
2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
2013 Breast Cancer Symposium,
American Society of Breast Surgeons, San Francisco, California - 9/7/2013

Press Mentions

Lajos Pusztai, MD, DPhil, Named a Giant of Cancer Care®May 8th, 2026
Head-To-Head Trial Establishes T-DXd as Superior Second-Line Treatment for Some Gastric, GEJ CancersJune 3rd, 2025
Cryotherapy for Chemotherapy Neuropathy: Does It Work?March 14th, 2025

Grant Support

Serum biomarkers to predict immune related adverse events and benefit from single agent pembrolizumab therapy in early stage triple negative breast cancerARIZONA STATE UNIVERSITY-TEMPE CAMPUS2023–2028